Molecular mechanisms of drug resistance

By D. Longley, P. Johnston. Journal of Pathology, 2005

1,664 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/2f1d07fd4f2f0f738f193631f7cbf90526bf630e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Mechanisms of chemoresistance in cancer stem cells (2013, background): “Currently, the complete elimination of cancer continues to elude oncologists as 90% of drug failures in metastatic cancers are attributed to chemoresistance [3].”
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge (2019, background): “Chemotherapy resistance presents a significant hurdle for successful cancer treatment, especially in the metastatic setting where it accounts for 90% of therapy failure [12].”
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors (2011, background): “Tumor drug resistance is thought to occur at many levels, including increased drug efflux, drug inactivation, evasion from apoptosis, and alterations in target pathways (53).”
The Different Mechanisms of Cancer Drug Resistance: A Brief Review (2017, background): “340 | Advanced Pharmaceutical Bulletin, 2017, 7(3), 339-348 Mansoori et al.”
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells (2007, methodology): “1 4 7 10 14 17 Anti-VEGF Control mFlt(1-3)-IgG”
5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies (2008, background): “Anti-cancer drug resistance can result from various causes including alteration of drug influx and efflux, enhancement of drug inactivation and mutation of the drug target [47].”
Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease (2015, neutral): “Unfortunately, a significant number of chemotherapeutic agents are carcinogenic or mutagenic, resulting in a higher frequency of mutations in the tumor, which leads to drug resistance [432].”
The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. (2014, background): “Inhibition of PARP1 was proven to enhance the cytotoxicity of DNA-damaging agents to cancer cells [12,13].”
Drug Resistance in Leishmaniasis (2006, neutral): “Although resistance mechanisms differ between prokaryotic and eukaryotic organisms, some general principles can be identified (68, 79).”